Trends in Mid-sized European Licensing
Executive Summary
Mid-sized European drug firms have traditionally spent considerably more on in-licensing than they've received from licensing out their products to other partners. But over the past two years, we've detected a dramatic shift in the ratio of dollars spent versus received in alliances.
You may also be interested in...
Trends in Mid-sized European Licensing
On balance, do mid-sized European players receive more licensing dollars from out-licensing than they spend on in-licensing?
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.